Phase 2 N=80 Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 2 N=96 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…
Phase 2 N=57 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Phase 2 N=211 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) by BICR Based on IWG Criteria — 78.3; 64.2; 73.3 Percentage of participants
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=28 Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants
Phase 2 N=25 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
Phase 2 N=129 Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants
Phase 2 N=39 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Phase 1 N=45 Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Part A (Dose Escalation): Number of Participants With Adverse Events (AEs) — 1; 1; 1; 1 Participants
Phase 4 N=60 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 50 percentage of participants
Phase 2 N=36 Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Hodgkin's Disease · Lymphoma
Primary: Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL. — 56 percentage of evaluable participants
Phase 2 N=118 Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
Phase 2 N=3 Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma · Classical Hodgkin Lymphoma
Primary: Maximum Tolerable Dose (Phase I) — NA Participants
Phase 2 N=70 A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 87.1 Percentage of Participants — p=<0.0001
Phase 2 N=45 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg
Phase 2 N=46 Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 64.3; 64.5; 64.4 Percentage of Participants — p=0.0044
Phase 2 N=24 Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients
Phase 1 N=133 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=24 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR) — 16.7 percentage of patients
Phase 2 N=58 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I) — 1; 2; 3; 0 Participants
Phase 2 N=20 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma
Primary: Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin…
Phase 2 N=20 Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Progression-Free Survival According to the Cheson Criteria by Kaplan-Meier Analysis Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin…
Phase 2 N=48 Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma
Primary: Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or…
Phase 2 N=66 A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Hodgkin's Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary: Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator — 66.7; 50.0 Percentage of Participants
Phase 2 N=56 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Panobinostat + ICE — 30 mg
Phase 2 N=25 Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Lymphoma
Primary: Progression-free Survival at 1 Year — 33.3 proportion of progression-free pts
Phase 2 N=110 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
AIDS-Related Hodgkin Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Follicular Lymphoma
Primary: Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only — 1; 0; 3; 0 Participants
Phase 2 N=29 Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Lymphoma
Primary: Overall Response — 3 participants